Advanced Accelerator Applications SA
At Advanced Accelerator Applications (AAA), we are reimagining nuclear medicine and cancer care. Our mission is to transform patients’ lives by developing and delivering targeted radioligand therapies and precision imaging radioligands for oncology. Our expertise is built on a more than 15-year legacy of manufacturing a portfolio of PET and SPECT nuclear medicine imaging products for a number of indications in oncology, neurology, cardiology and infectious & inflammatory diseases. AAA operates in Canada, France, Germany, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the U.S., while its distribution network covers more than 30 countries.
AAA is an innovative medicines company focused on the development of products for targeted radioligand therapy and precision radioligand imaging.
AAA currently markets 1 targeted radioligand therapy in oncology and several precision imaging products mainly used in clinical oncology, cardiology, neurology and infectious/inflammatory diseases.
We also have an active research and development pipeline of investigational drugs using radiolabeled targeting molecules in multiple cancer types.
Our business is structured to improve efficiencies and drive innovation. We are able to generate or reliably source radioisotopes such as fluorine 18 (F-18) and lutetium 177 (Lu-177), and conduct much of our own research and development, in addition to having in-house commercial manufacturing and marketing capabilities.
- AAA currently has a total of 29 sites in 12 countries, including: 19 production facilities in 8 countries (in Europe and the U.S.) that manufacture targeted radioligand therapies and precision imaging radioligands
- 6 sites with R&D activity
All of our manufacturing facilities conform to current good manufacturing practices or cGMP. This network provides the basis for our advanced manufacturing capacity, cost-efficient production, and organization of reliable product distribution.
Advanced Accelerator Applications (AAA), was founded in 2002, by physicist Stefano Buono, who was inspired to pursue medical applications for certain research conducted during his tenure at the European Organization for Nuclear Research, or CERN, with Nobel laureate Carlo Rubbia.
We are proud to support patient groups, academic research institutions, industry associations and other partners as part of our mission to transform patients’ lives.
As a Novartis Company, AAA may provide external funding to legitimate organizations in the interest of driving its mission to improve healthcare, advance scientific/medical knowledge or support the communities where AAA associates live and work.
We ensure that our interactions with all of our stakeholders are based on the highest ethical standards and compliant with all applicable laws, regulations and industry codes and we strive to build relationships based on transparency, mutual respect and shared goals.
For information on AAA UK Patient Group Partnering and Joint Working Initiatives, please click here.
Applying for funding
Applications must outline a clear and defined purpose and transparent objectives, deliverables, milestones and outcomes as appropriate and directly related to AAA Areas of Interest.
Applications will only be accepted from legitimate organizations and not to individuals. The applicant will be responsible for the application, content and implementation of any activity that receives AAA support, including compliance with laws and regulations.
Funding may be provided in the form of grants. A grant is an unsolicited, independently requested monetary contribution for a specified purpose to support medical/scientific research, education, policy initiatives, and patient advocacy activities. Grants will not be provided to political parties. Please note that an Investigator Initiated Trial (IIT) or study funding request is not to be considered as a grant.